Regulus Therapeutics (id:6001 RGLS)
1.47 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 3:58:14 PM)
Exchange closed, opens in 1 day 17 hours
2.08 USD (2.08%)
2.80 USD (2.80%)
-2.00 USD (-2.00%)
-28.29 USD (-28.29%)
8.89 USD (8.89%)
-78.70 USD (-78.70%)
-99.93 USD (-99.93%)
-99.74 USD (-99.74%)
About Regulus Therapeutics
Market Capitalization 91.70M
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
| Headquarters (address) |
4224 Campus Point Court San Diego 92121 CA United States |
| Phone | 858 202 6300 |
| Website | https://www.regulusrx.com |
| Employees | 30 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | RGLS |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.08 - 3.79 |
| Market Capitalization | 91.70M |
| P/E trailing | -0.930 |
| P/E forward | -1.16 |
| Price/Book | 1.06 |
| Beta | 1.63 |
| EPS | -1.02 |
| EPS United States (ID:6, base:3402) | 24.25 |